文献速递膀胱癌与上尿路尿路上皮癌

既往非肌层浸润性膀胱癌对肌层浸润性膀胱癌新辅助化疗疗效的预测价值:BLADRAC队列真实世界分析

Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort.
PubMed 文献 · Eur Urol Oncol · 2025-12-18

该真实世界研究纳入2378例接受根治性膀胱切除术的肌层浸润性膀胱癌患者,其中37%接受新辅助化疗。既往非肌层浸润性膀胱癌患者接受新辅助化疗的可能性显著更低(OR=0.63),但既往非肌层浸润性膀胱癌与病理完全缓解、病理客观缓解及生存结局均无显著关联,且不影响新辅助化疗的疗效。

要点

  • 既往NMIBC患者接受NAC的几率显著低于原发性MIBC患者(OR=0.63)。
  • NAC独立预测更优的pCR、pOR、RFS、CSS和OS。
  • 既往NMIBC与NAC疗效之间无显著交互作用(所有p交互>0.05)。

核心结论

  • 真实世界数据显示,既往非肌层浸润性膀胱癌可能限制新辅助化疗的可及性,但不能预测其疗效。

研究设计与样本

  • 多中心回顾性队列研究(BLADRAC),纳入2001至2023年15家法国中心2378例接受根治性膀胱切除术的肌层浸润性膀胱癌患者。
  • 其中870例(37%)接受新辅助化疗,1508例(63%)未接受;原发性肌层浸润性膀胱癌1825例(77%),继发性553例(23%)。

主要发现

  • 继发性肌层浸润性膀胱癌患者接受新辅助化疗的可能性显著低于原发性患者(OR=0.63;95%CI=0.5-0.79;p<0.001)。
  • 新辅助化疗独立预测更好的病理完全缓解(OR=6.02;95%CI=4.63-7.83;p<0.001)和病理客观缓解(OR=5.08;95%CI=4.09-6.3;p<0.001)。
  • 新辅助化疗独立预测更好的无复发生存(HR=0.61;95%CI=0.53-0.71;p<0.001)、癌症特异性生存(HR=0.57;95%CI=0.47-0.69;p<0.001)和总生存(HR=0.61;95%CI=0.51-0.72;p<0.001)。
  • 既往非肌层浸润性膀胱癌与上述任何终点均无显著关联(所有p>0.05)。
  • 既往非肌层浸润性膀胱癌与新辅助化疗对病理完全缓解、病理客观缓解、无复发生存、癌症特异性生存和总生存的影响之间无显著交互作用(所有p交互>0.05)。

临床怎么用

  • 对于有既往非肌层浸润性膀胱癌病史的肌层浸润性膀胱癌患者,不应基于既往病史限制新辅助化疗的使用,因其疗效与原发性患者相似。

局限性

  • 研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: It remains currently unknown whether the effectiveness of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) is the same in patients with or without prior non-muscle invasive bladder cancer (NMIBC). This study aims to perform a real-world analysis of the predictive value of prior NMIBC for the effectiveness of NAC in patients undergoing RC for MIBC. METHODS: We included 2378 patients from the BLADRAC cohort who received RC with (n = 870; 37%) or without (n = 1508; 63%) NAC for primary (n = 1825; 77%) or secondary (n = 553; 23%) MIBC at 15 French centers from 2001 to 2023. Multivariable logistic regression models were fitted to identify the predictors of NAC delivery as well as those of pathological complete (pCR = [y]pT0N0) and pathological objective (pOR ≤[y]pT1N0) responses, while we assessed the predictors of recurrence-free (RFS), cancer-specific (CSS), and overall (OS) survival using multivariable Cox regression models. The heterogeneity of treatment effect of NAC according to the occurrence of prior NMIBC was determined further by testing the interaction terms between the occurrence of prior NMIBC and the effect of NAC within the models evaluating pathological and survival outcomes. KEY FINDINGS AND LIMITATIONS: Patients with secondary MIBC were significantly less likely to receive NAC (odds ratio [OR] = 0.63; 95% confidence interval [CI] = [0.5-0.79]; p < 0.001) than those with primary MIBC. The use of NAC was an independent predictor of better pCR (OR = 6.02; 95% CI = [4.63-7.83]; p < 0.001), pOR (OR = 5.08; 95% CI = [4.09-6.3]; p < 0.001), RFS (HR = 0.61; 95% CI = [0.53-0.71]; p < 0.001), CSS (HR = 0.57; 95% CI = [0.47-0.69]; p < 0.001), and OS (HR = 0.61; 95% CI = [0.51-0.72]; p < 0.001), while the occurrence of prior NMIBC was not significantly associated with any of these endpoints (all p > 0.05). There was no significant interaction between the occurrence of prior NMIBC and the impact of NAC on pCR, pOR, RFS, CSS, and OS (all pinteraction > 0.05). The study is limited by its retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our real-world data suggest that the occurrence of prior NMIBC could limit the access to NAC, while not predicting its effectiveness in patients treated with RC for localized MIBC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Grobet-Jeandin E, Diamant E, Gabriel PE, et al. Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort. Eur Urol Oncol. 2025. PMID: 41419411. doi:10.1016/j.euo.2025.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。